Asian Journal of Andrology | 2019
Separate Chinese lines for prostate cancer?
Abstract
a varying number of participants in the trial. Some centers recruited less than 10 participants, but many centers recruited more than 100 participants. Overall the STAMPEDE trial analyzed nearly 9000 participants. A similar Chinese multicenter trial organization may recruit more participants. In the 1990s, it was shown that East-Asian female nonsmoking patients with nonsmall cell lung cancer often had mutations of the epidermal growth factor receptor (EGFR). Treatment with EGFR inhibitors gave a high response for patients with mutations of EGFR.7 Randomized trials showed that EGFR inhibitors gave patients with EGFR mutations as effective results as established chemotherapy. Correspondingly, studies of Chinese patients with prostate cancer might disclose that Asian and Western prostate cancers have important genetic differences. Recent years have given many changes in the treatment of prostate cancer. China might organize a National database of all patients with prostate cancer as has been done in Denmark. The database should be structured so it could provide feedback to health authorities and other interested parties. A Chinese database of prostate cancer might further elucidate whether guidelines based on Western populations are relevant for Asian populations. It will be of interest for a Western oncologist to follow future Chinese clinical research of prostate cancer.